Glucotrack, Inc. (GCTK) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Glucotrack, Inc. is a medical device company focused on developing an Implantable Continuous Glucose Monitor (CGM) for Type 1 and insulin-dependent Type 2 diabetes patients. The company has withdrawn its previous CE Mark for a non-invasive earlobe sensor to focus exclusively on the implantable CGM. A regulatory submission for a first-in-human study is expected to initiate in Q3 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4.49M) | $(7.42M) | $(1.18M) | $(2.46M) |
| Operating Expenses | $(4.49M) | $(7.44M) | $(1.18M) | $(2.46M) |
| Cash & Equivalents (End of Period) | $0.16M | $0.16M | N/A | N/A |
| Accumulated Deficit | $(117.27M) | $(117.27M) | $(105.22M) | $(105.22M) |
| Net Cash Used in Operations | N/A | $(4.85M) | N/A | $(2.27M) |
Note: Financial figures are in thousands of US dollars unless otherwise noted. The company reported no revenue for any period presented.
Material Changes vs. Prior Period
- Expense Surge: Research and Development (R&D) expenses increased significantly to $3.59M for Q2 2024 from $0.63M in Q2 2023, driven by ramping up product development activities. Total operating expenses for the six months ended June 30, 2024, were $7.44M compared to $2.46M in the prior year period.
- Liquidity Decline: Cash and cash equivalents dropped from $4.49M at December 31, 2023, to $0.16M at June 30, 2024, due to high operating burn rates.
- Capital Structure: The company executed a 1-for-5 reverse stock split in May 2024. Additionally, the company raised $0.58M in financing activities during the first half of 2024 (private placements and notes), compared to $8.73M in the same period in 2023.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With only $0.16M in cash as of June 30, 2024, the company states it does not have sufficient working capital to fund operations for the next 12 months without additional financing.
- Recent Financing: Subsequent to the balance sheet date, the company raised approximately $4.36M through convertible promissory notes and other agreements (July 2024) to extend its runway.
- Nasdaq Compliance: The company is under review for failing to meet Nasdaq's Minimum Bid Price and Minimum Stockholders' Equity requirements. A hearing panel granted an extension until November 18, 2024, to regain compliance. Failure to comply could result in delisting.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2024, citing material weaknesses related to insufficient internal accounting personnel and segregation of duties.
- Product Milestones: The company achieved a second performance milestone in May 2024 regarding an IP purchase agreement, triggering an obligation to issue 30,000 restricted shares.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.36M raised in July 2024 against the current burn rate to confirm the timeline for the next capital raise.
- Nasdaq Status: Monitor the company's progress toward meeting the $2.5M stockholders' equity and $1.00 minimum bid price requirements by the November 18, 2024 deadline.
- Internal Controls: Review future filings for evidence of remediation regarding the identified material weaknesses in financial reporting.
- Regulatory Progress: Confirm the initiation of the first-in-human clinical trial in Q3 2024 as planned.
- Dilution Risk: Assess the impact of outstanding warrants and convertible notes (including the $4M secured note from July 2024) on future share count and ownership dilution.